{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:50Z","timestamp":1790891690737,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:22:00Z","timestamp":1784924520000},"page":"601-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Alec","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eraky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.009_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.06.009_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.009_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.009_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.06.009_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101925","article-title":"The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma","volume":"82","author":"Powles","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.009_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.009_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7867","key":"10.1016\/j.ucl.2026.06.009_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.009_bib14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.009_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.ucl.2026.06.009_bib16","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","article-title":"Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial","volume":"86","author":"Plimack","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.009_bib19","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.009_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.009_bib21","doi-asserted-by":"crossref","first-page":"TPS4615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (alliance A031701)","volume":"40","author":"Iyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155960","article-title":"Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder cancer","volume":"270","author":"Ebner","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.009_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.009_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.009_bib26","doi-asserted-by":"crossref","first-page":"TPS580","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS580","article-title":"Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: a randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302)","volume":"40","author":"Cole","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.009_bib27","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome","volume":"70","author":"Lindgren","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.009_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib30","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"issue":"10031","key":"10.1016\/j.ucl.2026.06.009_bib31","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"7693","key":"10.1016\/j.ucl.2026.06.009_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.009_bib33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ucl.2026.06.009_bib35","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ucl.2026.06.009_bib37","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"7471","key":"10.1016\/j.ucl.2026.06.009_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.009_bib39","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (checkMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.009_bib40","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"34","key":"10.1016\/j.ucl.2026.06.009_bib41","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/djaa076","article-title":"Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"113","author":"Bandini","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.ucl.2026.06.009_bib43","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.009_bib44","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","author":"Raggi","year":"2025","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.06.009_bib46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.009_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oncolo\/oyae198","article-title":"High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions","volume":"29","author":"Patel","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.009_bib48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.009_bib49","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.009_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.ucl.2026.06.009_bib51","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical Follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.009_bib52","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.009_bib53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.009_bib54","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.009_bib55","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.009_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.009_bib57","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.euo.2025.04.027","article-title":"Bladder cancer with undetectable circulating tumor DNA after radical cystectomy may be amenable to a less intense imaging surveillance protocol: a diagnostic accuracy study","volume":"8","author":"Eraky","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.009_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.06.009_bib59","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.06.009_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-Guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.009_bib61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2023.41.6_suppl.563","article-title":"Utility of ctDNA in predicting outcome and pathological complete response in patients with bladder cancer as a guide for selective bladder preservation strategies","volume":"41","author":"Dyrskj\u00f8t","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.009_bib62","article-title":"Early detection of metastatic progression by circulating tumor DNA in patients undergoing bladder-preserving trimodality therapy","volume":"13","author":"Zhao","year":"2025","journal-title":"J Urol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.009_bib63","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2025.43.16_suppl.4602","article-title":"Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT)","volume":"43","author":"Epstein","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:00Z","timestamp":1790888340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000625"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}